Prostate Cancer
Key Points
- Prostate cancer is a common male malignancy and often grows slowly in early stages.
- Early disease may have minimal urinary symptoms; advanced disease can present with systemic and metastatic cues.
- PSA can be elevated in cancer, BPH, or prostatitis, so diagnosis requires integrated testing and biopsy.
- Staging may include PSMA PET, transrectal imaging/biopsy methods, and metastasis imaging (bone scan, CT, MRI).
- Treatment options include watchful waiting, surgery, radiation/radiopharmaceutical therapy, hormone therapy, and systemic therapy.
Pathophysiology
Prostate cancer commonly arises in peripheral prostate zones, which may delay early outlet-obstruction symptoms. Tumor growth can remain indolent for long periods or progress to local invasion and distant metastasis.
Advanced disease may spread to bone, lymph nodes, and other organs, producing pain, fatigue, anemia-related findings, and broader functional decline.
Classification
- Localized/early disease: May be asymptomatic or mimic mild lower urinary tract symptoms.
- Locally advanced disease: Greater local tissue involvement and rising symptom burden.
- Metastatic disease: Spread outside prostate, frequently to bone and lymphatic structures.
- Screening-decision context: PSA-based screening in men 55-69 is an individualized shared decision after discussion of potential benefits and harms.
Nursing Assessment
NCLEX Focus
Differentiate BPH-like urinary symptoms from malignant progression cues and assess for metastatic warning signs.
- Assess early urinary symptoms overlapping with BPH (hesitancy, nocturia, incomplete emptying).
- Assess advanced/metastatic cues: persistent back/hip/pelvic pain, dyspnea, fatigue, pallor, dizziness, hematuria, hematospermia, dysuria, and erectile dysfunction.
- Review diagnostic data: DRE findings, PSA trends, biopsy results, and imaging for local spread or distant metastasis.
- Track treatment burden and functional impact across surgical, radiation, hormonal, and systemic therapies.
- Assess emotional distress, body-image and intimacy concerns, and family coping needs during prolonged treatment pathways.
Nursing Interventions
- Support stage-based treatment planning and reinforce rationale for watchful waiting when selected.
- Reinforce PSA-screening counseling as a shared decision process rather than automatic universal testing.
- Prepare clients for diagnostic and therapeutic procedures (biopsy, surgery, radiation planning, hormone pathways).
- Monitor for treatment-related complications and reinforce symptom-reporting thresholds.
- Support pain and fatigue management, especially when metastatic bone involvement is present.
- Reinforce infection-warning education after chemotherapy or surgery and prompt reporting expectations.
- Screen for anxiety/depression, reinforce coping strategies (including relaxation/mindfulness), and coordinate counseling/support-group referral.
- Offer palliative-care services for symptom control and quality-of-life support; discuss advance-care planning and end-of-life preferences when indicated.
Metastatic Bone Risk
Persistent skeletal pain in prostate-cancer clients may indicate bone metastasis and requires prompt assessment and treatment escalation.
Pharmacology
| Drug Class | Examples | Key Nursing Considerations |
|---|---|---|
| hormonal-therapy | anti-androgen context | Hormone therapy (androgen suppression) reduces tumor growth signaling. |
| bisphosphonates | class-based agents | Used when bone metastasis or treatment-related bone loss risk is present. |
| chemotherapy | systemic context | Used in selected advanced pathways with close adverse-effect monitoring. |
| targeted-therapy | class-based agents | Molecularly guided options for advanced disease settings. |
| immunotherapy | class-based agents | Immune-modulating pathway for selected advanced cases. |
Clinical Judgment Application
Clinical Scenario
A client with known prostate cancer reports worsening hip pain, fatigue, and dizziness; imaging is ordered to evaluate possible metastatic spread.
- Recognize Cues: New persistent skeletal pain plus systemic decline cues.
- Analyze Cues: Symptoms may represent metastatic progression with anemia/bone involvement.
- Prioritize Hypotheses: Immediate priority is metastatic reassessment and symptom stabilization.
- Generate Solutions: Coordinate imaging/lab follow-up, optimize pain control, and reinforce escalation signs.
- Take Action: Implement orders, monitor treatment tolerance, and communicate deterioration promptly.
- Evaluate Outcomes: Disease status is clarified and treatment plan is adjusted for symptom control and quality of life.
Related Concepts
- benign-prostatic-hyperplasia - Key differential because early symptoms may overlap.
- bladder-cancer - Related urinary-system oncology pathway with different surgery/diversion focus.
- bladder-assessment - Urinary pattern and hematuria cue interpretation supports early escalation.
- erectile-dysfunction - May occur as disease symptom or treatment-related consequence.
- palliative-care - Supports symptom relief and goals-of-care alignment in advanced prostate-cancer care.
Self-Check
- Why is PSA alone insufficient to diagnose prostate cancer?
- Which symptom cluster suggests metastatic progression rather than localized disease?
- When is watchful waiting preferred, and what nursing follow-up is essential?